Revolution Medicines (RVMD) COO Horn exercises options, sells stock

Q: What insider activity did RVMD COO Margaret Horn report on this Form 4?

Chief Operating Officer Margaret A. Horn reported exercising stock options and selling common shares of Revolution Medicines, Inc. (RVMD) on January 7, 2026 . She exercised options for 51,406 shares at $42.45 and 23,594 shares at $29.80 , then sold multiple blocks of common stock on the same date.

Q: How many Revolution Medicines (RVMD) shares did Margaret Horn sell and at what prices?

On January 7, 2026 , Margaret Horn sold 53,096 , 20,204 , and 1,700 shares of Revolution Medicines common stock. The weighted average sale prices were $100.0164 , $101.7928 , and $102.90 per share, respectively, with the filing noting each sale was executed in multiple trades within stated price ranges.

Q: What stock options in Revolution Medicines does the COO still hold after exercising some options?

After the January 7, 2026 exercises, the Form 4 shows remaining stock options for 1,094 shares at an exercise price of $42.45 and 119,906 shares at an exercise price of $29.80 , with vesting for the latter occurring in monthly installments from March 1, 2024 over four years.

Q: How do Margaret Horn’s RVMD options vest according to the Form 4 footnotes?

For one option grant, the filing explains that one forty-eighth (1/48th) of the shares initially subject to the option vest on each monthly anniversary of March 1, 2024 , so that 100% of the shares vest and become exercisable by the fourth anniversary of that vesting commencement date, subject to continued service.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported a series of option exercises and share sales on January 7, 2026. She exercised stock options for 51,406 shares of common stock at $42.45 per share and 23,594 shares at $29.80 per share, then sold 53,096, 20,204 and 1,700 shares of common stock at weighted average prices of $100.0164, $101.7928 and $102.90, respectively. The transactions were made under a Rule 10b5-1 trading plan adopted on March 7, 2025. After these trades, she directly beneficially owned 141,053 shares of common stock, which include 61,226 restricted stock units, and held remaining stock options covering 1,094 and 119,906 shares with vesting described in the filing.

Insider Trade Summary

Net Seller: 75,000 shares ($7,542,023)

Net Sell 7 txns

Insider Horn Margaret A

Role Chief Operating Officer

Sold 75,000 shs ($7.54M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	51,406	$0.00	--
Exercise	Stock Option (Right to Buy)	23,594	$0.00	--
Exercise	Common Stock	51,406	$42.45	$2.18M
Exercise	Common Stock	23,594	$29.80	$703K
Sale	Common Stock	53,096	$100.0164	$5.31M
Sale	Common Stock	20,204	$101.7928	$2.06M
Sale	Common Stock	1,700	$102.90	$175K

Holdings After Transaction: Stock Option (Right to Buy) — 1,094 shares (Direct); Common Stock — 192,459 shares (Direct)

Footnotes (1)

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025. Includes 61,226 restricted stock units. This transaction was executed in multiple trades in prices ranging from $100.00 to $100.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $101.07 to $101.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

01/09/2026 - 04:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horn Margaret A

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

94063

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/07/2026		M⁽¹⁾		51,406	A	$42.45	192,459⁽²⁾	D
Common Stock	01/07/2026		M⁽¹⁾		23,594	A	$29.8	216,053⁽²⁾	D
Common Stock	01/07/2026		S⁽¹⁾		53,096	D	$100.0164⁽³⁾	162,957⁽²⁾	D
Common Stock	01/07/2026		S⁽¹⁾		20,204	D	$101.7928⁽⁴⁾	142,753⁽²⁾	D
Common Stock	01/07/2026		S⁽¹⁾		1,700	D	$102.9	141,053⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$42.45	01/07/2026		M⁽¹⁾			51,406	08/09/2023	03/03/2031	Common Stock	51,406	$0	1,094	D
Stock Option (Right to Buy)	$29.8	01/07/2026		M⁽¹⁾			23,594	⁽⁵⁾	02/28/2034	Common Stock	23,594	$0	119,906	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025.

2. Includes 61,226 restricted stock units.

3. This transaction was executed in multiple trades in prices ranging from $100.00 to $100.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. This transaction was executed in multiple trades in prices ranging from $101.07 to $101.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

5. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

	/s/ Jack Anders, as Attorney-in-fact for Margaret Horn	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did RVMD COO Margaret Horn report on this Form 4?

Chief Operating Officer Margaret A. Horn reported exercising stock options and selling common shares of Revolution Medicines, Inc. (RVMD) on January 7, 2026. She exercised options for 51,406 shares at $42.45 and 23,594 shares at $29.80, then sold multiple blocks of common stock on the same date.

How many Revolution Medicines (RVMD) shares did Margaret Horn sell and at what prices?

On January 7, 2026, Margaret Horn sold 53,096, 20,204, and 1,700 shares of Revolution Medicines common stock. The weighted average sale prices were $100.0164, $101.7928, and $102.90 per share, respectively, with the filing noting each sale was executed in multiple trades within stated price ranges.

Was the RVMD COO’s trading done under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2025. Such plans allow pre-arranged trading of shares according to predetermined instructions.

How many RVMD shares does Margaret Horn own after these transactions?

Following the reported transactions, Margaret Horn beneficially owned 141,053 shares of Revolution Medicines common stock directly. This figure includes 61,226 restricted stock units as noted in the footnotes.

What stock options in Revolution Medicines does the COO still hold after exercising some options?

After the January 7, 2026 exercises, the Form 4 shows remaining stock options for 1,094 shares at an exercise price of $42.45 and 119,906 shares at an exercise price of $29.80, with vesting for the latter occurring in monthly installments from March 1, 2024 over four years.

How do Margaret Horn’s RVMD options vest according to the Form 4 footnotes?

For one option grant, the filing explains that one forty-eighth (1/48th) of the shares initially subject to the option vest on each monthly anniversary of March 1, 2024, so that 100% of the shares vest and become exercisable by the fourth anniversary of that vesting commencement date, subject to continued service.